It seems that the CDC brings good news at last. Check out the latest reports about the antibodies that people developed following the COVID shots.
CDC drops important COVID-related news
According to the Centers for Disease Control and Prevention, antibodies created from a prior COVID-19 infection or existing vaccines have been shown to effectively protect against a new variant discovered in the United States. This encouraging data is expected to support the latest COVID-19 vaccine booster shot, currently being evaluated by federal health agencies. The Food and Drug Administration is anticipated to authorize updated vaccines that target sub-variants of Omicron.
“Early research data from multiple labs are reassuring and show that existing antibodies work against the new BA.2.86 variant,” the CDC stated in an update on Sept. 8. “These data are also encouraging because of what it may mean for the effectiveness of the 2023–2024 COVID-19 vaccine, which is currently under review. That’s because the vaccine is tailored to the currently circulating variants.”
As per the latest update from the public health agency, the recent uptick in COVID-19 cases and hospitalizations in the United States cannot be attributed to the new BA.2.86 lineage of the virus.
The agency has identified other viruses that are predominantly circulating as the primary cause. Although the CDC’s initial risk assessment in August identified the presence of BA.2.86 in nine U.S. states, its impact on the current situation remains negligible. Additionally, the Omicron variant has been detected in human and wastewater specimens in Japan, the UK, and Canada.
“Additionally, based on CDC’s experience with past SARS-CoV-2 variants, people will likely have protection against severe disease mediated by both cellular and antibody immunity,” the agency stated.
The notes continued and revealed the following:
“Real-world data are needed to fully understand the impact given the complexities of the immune response to this variant. Additional studies on this are ongoing, and we expect to learn more in upcoming weeks.”